CEO Siddharth Mittal believes Biocon’s existing portfolio, including liraglutide, gives it an edge in a highly competitive market.
​CEO Siddharth Mittal believes Biocon’s existing portfolio, including liraglutide, gives it an edge in a highly competitive market. by Soban News (international And National News)
